Ionis (IONS) Lost $3 Billion Overnight. The Drug That 'Failed' Is Already Approved.
IONS fell more than 20% on the CARDIO-TTRansform miss, erasing ~$3 billion. But eplontersen is already an approved, selling drug — what failed was the cardiomyopathy expansion. The math on what survives, and the two FDA dates the selloff ignored.
Ionis Pharmaceuticals (NASDAQ: IONS) opened Thursday down more than 20%. By the pre-market session the stock had fallen from Wednesday's close of $84.46 to roughly $66 — erasing about $3 billion of market value in a few hours. The trigger was a single line in a pre-dawn press release: the Phase 3 CARDIO-TTRansform trial of eplontersen "did not meet its primary endpoint."
That is the headline every terminal flashed. It is also the part almost nobody is reading correctly.
The drug that "failed" is already on pharmacy shelves
Eplontersen is not an experimental molecule that just died in the lab. It has been approved and selling since 2023 under the brand name WAINUA, marketed with AstraZeneca for hereditary transthyretin-mediated amyloid polyneuropathy (ATTR-PN) — the nerve-damage form of the disease. That business is intact. It generated royalty revenue for Ionis last quarter and will generate more this quarter.
What failed on Thursday was the expansion. CARDIO-TTRansform was the trial designed to move eplontersen into the far larger cardiomyopathy market — ATTR-CM, the version of the disease that attacks the heart. ATTR-CM is a multi-billion-dollar arena currently dominated by Pfizer's tafamidis franchise, with BridgeBio and Alnylam fighting for share. Winning a slice of it was the upside case baked into eplontersen's peak-sales ceiling.
So the accurate framing is not "Ionis's drug failed." It is "Ionis lost a shot at a new, bigger market for a drug it already sells in a smaller one." Those are very different events — and the market just priced them as if they were the same.
The wrinkle the tape ignored
There is a further detail buried in the release. The trial missed on its overall population, but a prespecified subgroup of patients taking eplontersen as monotherapy showed a hazard ratio of 0.71 — a nominally significant 29% reduction in cardiovascular events. No benefit showed up in patients already on background therapy. That is not a clean win. But it is not a clean zero either, and the full dataset is scheduled for presentation at the European Society of Cardiology (ESC) Congress in August. A subgroup signal like that is the difference between "abandon the program" and "there may still be a path" — and it is exactly the kind of nuance a 22% gap-down does not stop to weigh.
Briefings like this land in members' inboxes before the market prices them in. Join free →
Why this is trending — and the real question
Ionis is not a single-drug biotech betting the company on one readout. It is a fully integrated commercial-stage company with seven marketed medicines, revenue growing at a double-digit clip, and two more FDA decisions due within four months. The cardiomyopathy miss removes an upside option. It does not touch the base business, the balance sheet, or the near-term catalyst calendar.
Which sets up the only question that matters for anyone holding — or watching — this ticker today:
Was a $3 billion markdown the right price for losing a market-expansion bet on one of seven drugs — or did a pre-market panic hand the tape the wrong number?
To answer that, you have to put actual figures on three things: what the base business is worth without ATTR-CM, how much runway the balance sheet actually buys, and what the next two catalysts could do to the stock. Here is the math.
The rest of this briefing is for paid members: the verified balance-sheet and revenue figures behind the $3 billion markdown, what eplontersen's cardiomyopathy market was actually worth and what survives the miss, the two confirmed FDA dates the selloff ignored, and scenario-by-scenario price zones tied to each catalyst.
AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish — the analysis private intel clients pay four figures for, at a fraction of that.